相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours
Mark T. J. van Bussel et al.
BRITISH JOURNAL OF CANCER (2021)
Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study
Emmanuel S. Antonarakis et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Revisiting Immunotherapy: A Focus on Prostate Cancer
Ha-Ram Cha et al.
CANCER RESEARCH (2020)
Peptide-Based Vaccines: Current Progress and Future Challenges
Ryan J. Malonis et al.
CHEMICAL REVIEWS (2020)
Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study
Wassim Abida et al.
CLINICAL CANCER RESEARCH (2020)
pVACtools: A Computational Toolkit to Identify and Visualize Cancer Neoantigens
Jasreet Hundal et al.
CANCER IMMUNOLOGY RESEARCH (2020)
PT-112 induces immunogenic cell death and synergizes with immune checkpoint blockers in mouse tumor models
Takahiro Yamazaki et al.
ONCOIMMUNOLOGY (2020)
Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: Results of cohort 6 of the COSMIC-021 study.
Neeraj Agarwal et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
A phase I/II study of GB1275, a first-in-class oral CD11b modulator, alone, and combined with pembrolizumab in specified advanced solid tumors or with chemotherapy in metastatic pancreatic cancer (KEYNOTE-A36).
Drew W. Rasco et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer
Sumit K. Subudhi et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)
Adi Diab et al.
CANCER DISCOVERY (2020)
Combination immunotherapy induces distinct T-cell repertoire responses when administered to patients with different malignancies
Jason Cham et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Olaparib for Metastatic Castration-Resistant Prostate Cancer
J. de Bono et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Multicenter Phase I Trial of a DNA Vaccine Encoding the Androgen Receptor Ligand-binding Domain (pTVG-AR, MVI-118) in Patients with Metastatic Prostate Cancer
Christos E. Kyriakopoulos et al.
CLINICAL CANCER RESEARCH (2020)
A Genetic Vaccine Encoding Shared Cancer Neoantigens to Treat Tumors with Microsatellite Instability
Guido Leoni et al.
CANCER RESEARCH (2020)
Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial
Federica Cappuccini et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA
Pedro Barata et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial
Padmanee Sharma et al.
CANCER CELL (2020)
An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma
Ugur Sahin et al.
NATURE (2020)
Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors
Karim Fizazi et al.
EUROPEAN UROLOGY (2020)
Comparison of Current Systemic Combination Therapies for Metastatic Hormone-Sensitive Prostate Cancer and Selection of Candidates for Optimal Treatment: A Systematic Review and Bayesian Network Meta-Analysis
Junru Chen et al.
FRONTIERS IN ONCOLOGY (2020)
Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
Rilan Bai et al.
BIOMARKER RESEARCH (2020)
Cell-Free DNA Alterations in the AR Enhancer and Locus Predict Resistance to AR-Directed Therapy in Patients With Metastatic Prostate Cancer
Ha X. Dang et al.
JCO PRECISION ONCOLOGY (2020)
CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors
Emmanuel S. Antonarakis et al.
JCO PRECISION ONCOLOGY (2020)
Bacillus Calmette-Guerin (BCG) Therapy for Bladder Cancer: An Update
Sandra Guallar-Garrido et al.
IMMUNOTARGETS AND THERAPY (2020)
Finding an Immunologic Beachhead in the Prostate Cancer Microenvironment
Ravi A. Madan et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)
First-Line Treatment of Non-Small-Cell Lung Cancer (NSCLC) with ImmuneCheckpoint Inhibitors
Olivier Bylicki et al.
BIODRUGS (2019)
Sequential therapy with ramucirumab and/or checkpoint inhibitors for non-small-cell lung cancer in routine practice
Cliff Molife et al.
FUTURE ONCOLOGY (2019)
Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer
James L. Gulley et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy
Shuang Qin et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Brian I. Rini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Targeting Protein Kinases to Enhance the Response to anti-PD-1/PD-L1 Immunotherapy
Marilina Garcia-Aranda et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Review of PD-1/PD-L1 Inhibitors in Metastatic dMMR/MSI-H Colorectal Cancer
Andre F. Oliveira et al.
FRONTIERS IN ONCOLOGY (2019)
ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer
Andrew J. Armstrong et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications
Yuxin Lin et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
Ian D. Davis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
Kim N. Chi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Supercharging adoptive T cell therapy to overcome solid tumor-induced immunosuppression
Sherly Mardiana et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Agonism of CD11b reprograms innate immunity to sensitize pancreatic cancer to immunotherapies
Roheena Z. Panni et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Immune Checkpoint Blockade Enhances Shared Neoantigen-Induced T-cell Immunity Directed against Mutated Calreticulin in Myeloproliferative Neoplasmas
Cansu Cimen Bozkus et al.
CANCER DISCOVERY (2019)
Targeted APC Activation in Cancer Immunotherapy to Enhance the Abscopal Effect
Nathan Suek et al.
FRONTIERS IN IMMUNOLOGY (2019)
Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer
Alessandro Leonetti et al.
DRUG RESISTANCE UPDATES (2019)
Prospects for combining immune checkpoint blockade with PARP inhibition
Anping Li et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Immunohistochemistry of immune checkpoint markers PD-1 and PD-L1 in prostate cancer
Meenal Sharma et al.
MEDICINE (2019)
Neoantigen vaccine: an emerging tumor immunotherapy
Miao Peng et al.
MOLECULAR CANCER (2019)
Genomic Alteration Burden in Advanced Prostate Cancer and Therapeutic Implications
Matthew J. Ryan et al.
FRONTIERS IN ONCOLOGY (2019)
Targeting FOXA1-mediated repression of TGF-β signaling suppresses castration-resistant prostate cancer progression
Bing Song et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape
Xianjie Jiang et al.
MOLECULAR CANCER (2019)
Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP [MVI-816]) in Patients With Progressive, Nonmetastatic, Castration-Sensitive Prostate Cancer
Douglas G. McNeel et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
Derin B. Keskin et al.
NATURE (2019)
MDSC; the Most Important Cell You Have Never Heard Of
R. J. Tesi
TRENDS IN PHARMACOLOGICAL SCIENCES (2019)
An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer
Steven Feins et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Oligometastases in prostate cancer: Ablative treatment
Amalia Palacios-Eito et al.
WORLD JOURNAL OF CLINICAL ONCOLOGY (2019)
Integrin αvβ3-targeted radionuclide therapy combined with immune checkpoint blockade immunotherapy synergistically enhances anti-tumor efficacy
Haojun Chen et al.
THERANOSTICS (2019)
Genetically engineered T cells for cancer immunotherapy
Dan Li et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2019)
Chimeric Antigen Receptor T Cells: A Race to Revolutionize Cancer Therapy
Marion Subklewe et al.
TRANSFUSION MEDICINE AND HEMOTHERAPY (2019)
Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study
A. R. Hansen et al.
ANNALS OF ONCOLOGY (2018)
Defective HLA class I antigen processing machinery in cancer
Lei Cai et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies
Gwenaelle Gravis et al.
EUROPEAN UROLOGY (2018)
Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: American Society of Clinical Oncology Clinical Practice Guideline
Michael J. Morris et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
mRNA vaccines - a new era in vaccinology
Norbert Pardi et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma
M. R. Migden et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
S. L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Cancer immunotherapy using checkpoint blockade
Antoni Ribas et al.
SCIENCE (2018)
Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer
Karim Boudadi et al.
Oncotarget (2018)
Therapeutic Responses and Survival Effects of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castrate-Resistant Prostate Cancer: A Meta-analysis
Yong Joong Kim et al.
CLINICAL NUCLEAR MEDICINE (2018)
VANCE: First-in-human phase I study of a novel ChAdOx1-MVA 5T4 vaccine in low and intermediate risk prostate cancer.
Irina Redchenko et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
An open-label, phase 2 study of nivolumab in combination with either rucaparib, docetaxel, or enzalutamide in men with castration-resistant metastatic prostate cancer (mCRPC; CheckMate 9KD).
Karim Fizazi et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Phase II neoadjuvant and immunologic study of B7-H3 targeting with enoblituzumab in localized intermediate- and high-risk prostate cancer.
Eugene Shenderov et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
New Vaccine Technologies to Combat Outbreak Situations
Susanne Rauch et al.
FRONTIERS IN IMMUNOLOGY (2018)
A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours
Amit Maity et al.
BRITISH JOURNAL OF CANCER (2018)
Integrin CD11b activation drives anti-tumor innate immunity
Michael C. Schmid et al.
NATURE COMMUNICATIONS (2018)
High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors
Saman Maleki Vareki
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Immune checkpoint inhibitors: recent progress and potential biomarkers
Pramod Darvin et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2018)
Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer
Niranjan J. Sathianathen et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2018)
Transforming growth factor-β in stem cells and tissue homeostasis
Xin Xu et al.
BONE RESEARCH (2018)
5T4 oncofoetal antigen: an attractive target for immune intervention in cancer
Peter L. Stern et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
A second chance for telomerase reverse transcriptase in anticancer immunotherapy
Maurizio Zanetti
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis
B. Benzon et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2017)
Revised Overall Survival Analysis of a Phase II, Randomized, Double-Blind, Controlled Study of PROSTVAC in Men With Metastatic Castration-Resistant Prostate Cancer
Philip W. Kantoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer
Tomasz M. Beer et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial
Narek Shaverdian et al.
LANCET ONCOLOGY (2017)
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
S. J. Antonia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
S. S. Neelapu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
Karim Fizazi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
N. D. James et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Myeloid-derived suppressor cells are increased and correlated with type 2 immune responses, malnutrition, inflammation, and poor prognosis in patients with breast cancer
Kenji Gonda et al.
ONCOLOGY LETTERS (2017)
Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: challenges and opportunities
An-Liang Xia et al.
ONCOTARGET (2017)
Expression of PD-L1 in Hormone-naive and Treated Prostate Cancer Patients Receiving Neoadjuvant Abiraterone Acetate plus Prednisone and Leuprolide
Carla Calagua et al.
CLINICAL CANCER RESEARCH (2017)
PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression
Shiping Jiao et al.
CLINICAL CANCER RESEARCH (2017)
Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies
Kristin G. Anderson et al.
CANCER CELL (2017)
Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis
Francesco Massari et al.
TARGETED ONCOLOGY (2016)
PARP inhibitor combination therapy
Amy Drean et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2016)
Harnessing T cells to fight cancer with BiTE® antibody constructs - past developments and future directions
Matthias Klinger et al.
IMMUNOLOGICAL REVIEWS (2016)
Association of ARV7 expression with molecular and clinical characteristics in prostate cancer.
Himanshu Joshi et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
Lena M. Kranz et al.
NATURE (2016)
Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors
Bing-Lan Zhang et al.
SCIENCE CHINA-LIFE SCIENCES (2016)
Androgen receptor antagonists compromise T cell response against prostate cancer leading to early tumor relapse
Yang Pu et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer
Julie N. Graff et al.
ONCOTARGET (2016)
The Role of TAM Family Receptors in Immune Cell Function: Implications for Cancer Therapy
Magdalena Paolino et al.
CANCERS (2016)
Persistent Neutrophil to Lymphocyte Ratio >3 during Treatment with Enzalutamide and Clinical Outcome in Patients with Castration-Resistant Prostate Cancer
Vincenza Conteduca et al.
PLOS ONE (2016)
The Role of Myeloid-Derived Suppressor Cells in Patients with Solid Tumors: A Meta-Analysis
Shuo Zhang et al.
PLOS ONE (2016)
First in human (FIH) study of an OX40 agonist monoclonal antibody (mAb) PF-04518600 (PF-8600) in adult patients (pts) with select advanced solid tumors: Preliminary safety and pharmacokinetic (PK)/pharmacodynamic results
Omid Hamid et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
The PARP1 inhibitor BMN 673 exhibits immunoregulatory effects in a Brca1-/- murine model of ovarian cancer
Jing Huang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2015)
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma
Kathleen M. Mahoney et al.
CLINICAL THERAPEUTICS (2015)
Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer
Julia Stieglmaier et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2015)
Novel Roles of c-Met in the Survival of Renal Cancer Cells through the Regulation of HO-1 and PD-L1 Expression
Murugabaskar Balan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Unfolding the Mutational Landscape of Human Melanoma
Diwakar Davar et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2015)
In silico analyses of Wilms' tumor protein to designing a novel multi-epitope DNA vaccine against cancer
Saeed Khalili et al.
JOURNAL OF THEORETICAL BIOLOGY (2015)
Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy
Andrew B. Sharabi et al.
LANCET ONCOLOGY (2015)
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
Charles J. Ryan et al.
LANCET ONCOLOGY (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Christopher J. Sweeney et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Neoantigens in cancer immunotherapy
Ton N. Schumacher et al.
SCIENCE (2015)
Adenosine Receptor 2A Blockade Increases the Efficacy of Anti-PD-1 through Enhanced Antitumor T-cell Responses
Paul A. Beavis et al.
CANCER IMMUNOLOGY RESEARCH (2015)
The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies
Leisha A. Emens et al.
CANCER IMMUNOLOGY RESEARCH (2015)
CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer
Tomoe Higuchi et al.
CANCER IMMUNOLOGY RESEARCH (2015)
HIF-1α pathway: role, regulation and intervention for cancer therapy
Georgina N. Masoud et al.
ACTA PHARMACEUTICA SINICA B (2015)
Inhibition of immune checkpoints and vascular endothelial growth factor as combination therapy for metastatic melanoma: an overview of rationale, preclinical evidence, and initial clinical data
Patrick A. Ott et al.
FRONTIERS IN ONCOLOGY (2015)
PD-L1 is highly expressed in Enzalutamide resistant prostate cancer
Jennifer L. Bishop et al.
ONCOTARGET (2015)
Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen
Andrew B. Sharabi et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Bacillus Calmette-Guerin (BCG) Treatment Failures in Non-Muscle Invasive Bladder Cancer: What Truly Constitutes Unresponsive Disease
Ryan L. Steinberg et al.
BLADDER CANCER (2015)
Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade
Simon J. Dovedi et al.
CANCER RESEARCH (2014)
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
Janis M. Taube et al.
CLINICAL CANCER RESEARCH (2014)
Pten Null Prostate Epithelium Promotes Localized Myeloid-Derived Suppressor Cell Expansion and Immune Suppression during Tumor Initiation and Progression
Alejandro J. Garcia et al.
MOLECULAR AND CELLULAR BIOLOGY (2014)
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
Eugene D. Kwon et al.
LANCET ONCOLOGY (2014)
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Matthew M. Gubin et al.
NATURE (2014)
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Emmanuel S. Antonarakis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy REPLY
Tomasz M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
T. M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Relapse or Eradication of Cancer Is Predicted by Peptide-Major Histocompatibility Complex Affinity
Boris Engels et al.
CANCER CELL (2013)
The androgen receptor: a biologically relevant vaccine target for the treatment of prostate cancer
Brian M. Olson et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
Personalized peptide vaccination: a new approach for advanced cancer as therapeutic cancer vaccine
Masanori Noguchi et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment
Thomas F. Gajewski et al.
CURRENT OPINION IN IMMUNOLOGY (2013)
High tissue density of FOXP3+T cells is associated with clinical outcome in prostate cancer
Anna Flammiger et al.
EUROPEAN JOURNAL OF CANCER (2013)
Perturbation of NK cell peripheral homeostasis accelerates prostate carcinoma metastasis
Gang Liu et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov et al.
NATURE (2013)
Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells
Paul F. Robbins et al.
NATURE MEDICINE (2013)
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
C. Parker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
A2B adenosine receptor blockade inhibits growth of prostate cancer cells
Qiang Wei et al.
PURINERGIC SIGNALLING (2013)
Lower Baseline Prostate-specific Antigen Is Associated With a Greater Overall Survival Benefit From Sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) Trial
Paul F. Schellhammer et al.
UROLOGY (2013)
Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
Douglas Hanahan et al.
CANCER CELL (2012)
Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity
Timothy S. Fisher et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Radiotherapy Promotes Tumor-Specific Effector CD8+ T Cells via Dendritic Cell Activation
Anurag Gupta et al.
JOURNAL OF IMMUNOLOGY (2012)
Improved Overall Survival Trends of Men with Newly Diagnosed M1 Prostate Cancer: A SWOG Phase III Trial Experience (S8494, S8894 and S9346)
Catherine M. Tangen et al.
JOURNAL OF UROLOGY (2012)
Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
Alfons J. M. van den Eertwegh et al.
LANCET ONCOLOGY (2012)
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
Karim Fizazi et al.
LANCET ONCOLOGY (2012)
The mutational landscape of lethal castration-resistant prostate cancer
Catherine S. Grasso et al.
NATURE (2012)
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Tumor-Associated Antigens for Specific Immunotherapy of Prostate Cancer
Andrea Kiessling et al.
Cancers (2012)
Delineation of a Cellular Hierarchy in Lung Cancer Reveals an Oncofetal Antigen Expressed on Tumor-Initiating Cells
Marc Damelin et al.
CANCER RESEARCH (2011)
Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma
Evan J. Lipson et al.
CLINICAL CANCER RESEARCH (2011)
IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation
Wei Liao et al.
CURRENT OPINION IN IMMUNOLOGY (2011)
Waif1/5T4 Inhibits Wnt/β-Catenin Signaling and Activates Noncanonical Wnt Pathways by Modifying LRP6 Subcellular Localization
Birgit Kagermeier-Schenk et al.
DEVELOPMENTAL CELL (2011)
Drug Safety Is a Barrier to the Discovery and Development of New Androgen Receptor Antagonists
William R. Foster et al.
PROSTATE (2011)
Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
Philip W. Kantoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
Johann Sebastian de Bono et al.
LANCET (2010)
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer.
Philip W. Kantoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
CXCR4 Mediated Chemotaxis Is Regulated by 5T4 Oncofetal Glycoprotein in Mouse Embryonic Cells
Thomas D. Southgate et al.
PLOS ONE (2010)
The regulation of IL-10 production by immune cells
Margarida Saraiva et al.
NATURE REVIEWS IMMUNOLOGY (2010)
Viral vectors: from virology to transgene expression
D. Bouard et al.
BRITISH JOURNAL OF PHARMACOLOGY (2009)
Integrated Data From 2 Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trials of Active Cellular Immunotherapy With Sipuleucel-T in Advanced Prostate Cancer
Celestia S. Higano et al.
CANCER (2009)
Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients
Jennifer S. Ko et al.
CLINICAL CANCER RESEARCH (2009)
Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer
Ravi A. Madan et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2009)
The significance of OX40 and OX40L to T-cell biology and immune disease
Michael Croft et al.
IMMUNOLOGICAL REVIEWS (2009)
Safety and Immunological Efficacy of a DNA Vaccine Encoding Prostatic Acid Phosphatase in Patients With Stage D0 Prostate Cancer
Douglas G. McNeel et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients
Philippe O. Gannon et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2009)
PD-1 and its ligands in tolerance and immunity
Mary E. Keir et al.
ANNUAL REVIEW OF IMMUNOLOGY (2008)
Phase 1/2 dose-escalation study of a GM-CSF-Secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer
Celestial S. Higano et al.
CANCER (2008)
HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance
M. Campoli et al.
ONCOGENE (2008)
Clinical safety of a viral vector based prostate cancer vaccine strategy
Philip M. Arlen et al.
JOURNAL OF UROLOGY (2007)
Granulocyte macrophage colony-stimulating factor-secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer
Eric J. Small et al.
CLINICAL CANCER RESEARCH (2007)
Plasmid DNA vaccine encoding prostatic acid phosphatase is effective in eliciting autologous antigen-specific CD8+ T cells
Laura E. Johnson et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Death in patients with recurrent prostate cancer after radical prostatectomy: Prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality
Stephen J. Freedland et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer
Jeanny B. Aragon-Ching et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2007)
Anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) immunotherapy for the treatment of prostate cancer
R. Houston Thompson et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2006)
Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer
Eric J. Small et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy
Eric A. Reits et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Role of tyrosine kinase inhibitors in cancer therapy
A Arora et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
Opinion - Immunotherapy and chemotherapy - a practical partnership
RA Lake et al.
NATURE REVIEWS CANCER (2005)
Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity
LP Chen
NATURE REVIEWS IMMUNOLOGY (2004)
Self-representation in the thymus: An extended view
B Kyewski et al.
NATURE REVIEWS IMMUNOLOGY (2004)
Poor immunogenicity of a self/tumor antigen derives from peptide-MHC-I instability and is independent of tolerance
ZY Yu et al.
JOURNAL OF CLINICAL INVESTIGATION (2004)
DNA vaccines: An active immunization strategy for prostate cancer
JD Wolchok et al.
SEMINARS IN ONCOLOGY (2003)
Prostate cancer: a dynamic illness with shifting targets
DR Shaffer et al.
LANCET ONCOLOGY (2003)
Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy
M Chakraborty et al.
JOURNAL OF IMMUNOLOGY (2003)
Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity
A Diefenbach et al.
NATURE (2001)
LHRH analogues as anticancer agents: pituitary and extrapituitary sites of action
P Limonta et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2001)
Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells
EJ Small et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Uses of granulocyte-macrophage colony-stimulating factor in vaccine development
TL Warren et al.
CURRENT OPINION IN HEMATOLOGY (2000)
分享论文
